12/20
08:19 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/19
08:07 am
aqst
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]
Low
Report
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]
12/19
08:00 am
aqst
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Low
Report
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
12/17
02:00 pm
aqst
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]
Low
Report
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]
12/17
08:54 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.
12/17
06:10 am
aqst
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year [Yahoo! Finance]
Low
Report
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year [Yahoo! Finance]
12/2
08:07 am
aqst
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
12/2
08:00 am
aqst
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Medium
Report
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
11/12
08:00 am
aqst
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Low
Report
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
11/6
08:07 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/6
06:42 am
aqst
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/6
02:22 am
aqst
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
11/4
08:58 pm
aqst
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
11/4
04:40 pm
aqst
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/4
04:36 pm
aqst
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
07:20 am
aqst
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
10/25
09:38 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its price target raised by analysts at Leerink Partners from $12.00 to $13.00. They now have an "outperform" rating on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its price target raised by analysts at Leerink Partners from $12.00 to $13.00. They now have an "outperform" rating on the stock.
10/25
08:37 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/25
08:00 am
aqst
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
Low
Report
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
10/24
08:00 am
aqst
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
Low
Report
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
10/21
08:00 am
aqst
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
Low
Report
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
10/8
02:34 pm
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
9/30
02:44 pm
aqst
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate [Yahoo! Finance]
Low
Report
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate [Yahoo! Finance]
9/30
10:08 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
9/30
08:40 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $12.00 price target on the stock, up previously from $10.00.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "outperform" rating re-affirmed by analysts at Leerink Partners. They now have a $12.00 price target on the stock, up previously from $10.00.